Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 3Phase 3 2Phase 1 2

Status

Completed 10Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unknown × fluzoparib × Clear all
NCT04425876 2020-12-31

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
74 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡